Edition:
United States

Teva Pharmaceutical Industries Ltd (TEVA.N)

TEVA.N on New York Stock Exchange

17.30USD
18 Aug 2017
Change (% chg)

$0.20 (+1.17%)
Prev Close
$17.10
Open
$17.10
Day's High
$17.53
Day's Low
$17.10
Volume
1,985,632
Avg. Vol
2,311,924
52-wk High
$53.96
52-wk Low
$16.81

Latest Key Developments (Source: Significant Developments)

Appaloosa dissolves share stake in Teva Pharmaceutical, Goodyear Tire & Rubber
Monday, 14 Aug 2017 05:13pm EDT 

Aug 14 (Reuters) - Appaloosa LP::Appaloosa LP dissolves class A share stake in Charter Communications Inc - sec filing.Appaloosa LP dissolves share stake in Teva Pharmaceutical Industries Ltd - sec filing.Appaloosa LP takes share stake of 1.1 million shares in Ally Financial Inc.Appaloosa LP dissolves share stake in Goodyear Tire & Rubber Co - sec filing.Appaloosa LP cuts share stake in Kinder Morgan Inc from 5.3 million shares to 3.9 million shares - sec filing.Appaloosa LP ups share stake in Unitedhealth Group Inc by 55.7 percent to 467,000 shares.Appaloosa LP - change in holdings are as of June 30, 2017 and compared with the previous quarter ended as of March 31, 2017.  Full Article

Paulson & Co cuts share stake in Teva Pharmaceutical, Sanofi
Monday, 14 Aug 2017 05:10pm EDT 

Aug 14 (Reuters) - Paulson & Co:Paulson & Co Inc cuts share stake in Teva Pharmaceutical Industries Ltd by 38.7 percent to 6.7 million sponsored ADR - SEC filing.Paulson & Co Inc cuts share stake in Sanofi by 65.3 percent to 52,000 sponsored ADR.Paulson & Co Inc - Change in holdings are as of June 30, 2017 and compared with the previous quarter ended as of March 31, 2017.  Full Article

Teva announces FDA approval of QVAR redihaler inhalation aerosol
Monday, 7 Aug 2017 08:00am EDT 

Aug 7 (Reuters) - Teva Pharmaceutical Industries Ltd :Teva announces FDA approval of QVAR redihaler (beclomethasone dipropionate HFA) inhalation aerosol.Teva Pharmaceutical Industries Ltd - plans to discontinue sales of this current QVAR MDI formulation upon launch of qvarredihaler in Q1 of 2018.Teva Pharmaceutical Industries - QVAR redihaler inhalation aerosol expected to become commercially available to patients by prescription during Q1 2018.  Full Article

Teva Pharmaceutical management on Q2 results, CEO search
Thursday, 3 Aug 2017 08:43am EDT 

Aug 3 (Reuters) - Teva Pharmaceutical Industries Ltd ::CEO: Impact to Teva with at least one competitor to Copaxone 40 mg would be 20-25 cents/quarter to EPS.CEO: we anticipate closing or divesting 6 plants in 2017 and 9 plants in 2018.CEO: By end of 2017, synergies related to Allergen generics expected at about $1.6 billion.CEO: In 2017 we expect to generate more than 50 percent of generic revenues outside of U.S..CFO: We expect generics drug price erosion to accelerate in the rest of 2017.CFO: Copaxone amounts to 18 percent of revenue, down from 23 percent last year.Chairman: In search for new CEO, won't rush or compromise on quality.Chairman on Q2 results: disappointed, significant change required and we have a sense of urgency.Chairman: Savings from dividend cut would help pay down debt, invest in business.CFO confident won't see generic 40 mg copaxone competition in 2017, hope won't see any in 2018.CEO on splitting company: We evaluate the situation all the time and now we are doing the right thing.Chairman on CEO search: Looking for CEO level experience from major global pharmaceutical firms.  Full Article

Teva Q2 non-gaap earnings per share $1.02
Thursday, 3 Aug 2017 06:30am EDT 

Aug 3 (Reuters) - Teva Pharmaceutical Industries Ltd :Teva reports second quarter 2017 financial results.Teva pharmaceutical industries ltd - ‍2017 business outlook revised to non-gaap eps of $4.30 - $4.50​.Sees fy 2017 non-gaap earnings per share $4.30 to $4.50.Q2 non-gaap earnings per share $1.02.Q2 gaap loss per share $5.94.Q2 revenue rose 13 percent to $5.7 billion.Teva pharmaceutical industries ltd - a goodwill impairment charge of $6.1 billion related to u.s. Generics reporting unit in quarter.Teva pharmaceutical industries ltd - legal settlements and loss contingencies of $324 million in quarter.Teva pharmaceutical - ‍q2 results were lower than anticipated due to performance of u.s. Generics business & continued deterioration in venezuela​.Teva pharmaceutical industries ltd - ‍generic medicines revenues in q2 of 2017 were $3.1 billion, an increase of 20% compared to q2 of 2016​.Teva pharmaceutical industries ltd - ‍lowered outlook for 2017 non-gaap revenues to $22.8 - $23.2 billion​.Qtrly global revenues of copaxone were $1.0 billion, a decrease of 10% compared to q2 of 2016.Teva pharmaceutical industries ltd - ‍specialty medicines revenues in q2 of 2017 were $2.1 billion, down 9% compared to q2 of 2016​.teva-‍adjusted fy outlook considers impact of higher price erosion in u.s. Generics business, which will be in high single digits rate for remainder of year​.  Full Article

U.S. FDA approves BLA for proposed biosimilar to Herceptin (trastuzumab)
Monday, 31 Jul 2017 08:00am EDT 

July 31 (Reuters) - Teva Pharmaceutical Industries Ltd :Celltrion and Teva announce U.S. FDA acceptance of Biologics License Application for proposed biosimilar to Herceptin (trastuzumab).Says BLAs for both CT-P6 and CT-P10 have been accepted for filing by FDA for standard review.Says FDA regulatory action expected during first half of 2018.  Full Article

Teva announces launch of generic Epiduo in the united states
Friday, 28 Jul 2017 08:00am EDT 

July 28 (Reuters) - Teva Pharmaceutical Industries Ltd :Teva announces launch of generic Epiduo in the united states.Teva announces launch of generic Epiduo in the united states.Teva Pharmaceutical Industries Ltd - announced launch of generic epiduo(adapalene and benzoyl peroxide) gel, 0.1%/2.5% in U.S..  Full Article

U.S. Senator Claire McCaskill opioid investigation expands to include distributors and additional manufacturers‍​
Thursday, 27 Jul 2017 08:30am EDT 

July 27 (Reuters) - Allergan Plc :U.S. Senator Claire McCaskill opioid investigation expands to include distributors and additional manufacturers‍​.U.S. Senator Claire McCaskill - newest requests for documents, information from opioid manufacturers were sent to Mallinckrodt, Endo, Teva, Allergan‍ ​.U.S. Senator Claire McCaskill - request to McKesson, AmerisourceBergen, Cardinal Health Inc focused on their distribution of opioid products.  Full Article

Teva Pharm denies anti-competitive behavior with Cephalon
Monday, 17 Jul 2017 07:02am EDT 

July 17 (Reuters) - Teva Pharmaceutical Industries Ltd , TEVA.N::Said on Monday it does not believe it entered into "any anti-competitive behavior" with Cephalon..Said it strongly disagrees with the way the European Commission analyses patent settlement in the pharmaceutical sector..Said in a statement that it will cooperate fully with the European authorities in their inquiry..  Full Article

UK Supreme Court confirms ruling on Lilly's patent case
Wednesday, 12 Jul 2017 05:14am EDT 

July 12 (Reuters) - Eli Lilly And Co :UK Supreme Court confirms that products by Actavis would infringe Lilly's patent, dismisses Actavis' cross-appeal.  Full Article